Epidermal growth factor receptor (EGFR) inhibitor-induced rash: A consecutive patient series that illustrates the need for rigorous palliative trials

Journal of Palliative Medicine

Volumn 14, Issue 2, 2011, Pages 153-156

  Solomon, Benjamin M ^a   Jatoi, Aminah ^a  

^a MAYO CLINIC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTINEOPLASTIC AGENT; AZITHROMYCIN; BENZOYL PEROXIDE; CEFALEXIN; CETUXIMAB; CLINDAMYCIN; COCONUT OIL; COSMETIC; COTRIMOXAZOLE; DEXAMETHASONE; DOXYCYCLINE; EPIDERMAL GROWTH FACTOR RECEPTOR KINASE INHIBITOR; ERLOTINIB; FEXOFENADINE; FLUOCINOLONE; HYDROCORTISONE; HYDROXYZINE; METRONIDAZOLE; MINOCYCLINE; PANITUMUMAB; PIMECROLIMUS; SULFACETAMIDE; TEA TREE OIL; TETRACYCLINE; TRIAMCINOLONE;

ADULT; ARTICLE; CANCER PALLIATIVE THERAPY; COLORECTAL CANCER; CONTROLLED STUDY; DRUG ERUPTION; DRUG INDICATION; DRUG WITHDRAWAL; FEMALE; HEAD AND NECK CANCER; HUMAN; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; PANCREAS CANCER; PREDICTION; PRESCRIPTION; QUALITY OF LIFE; TOPICAL TREATMENT;

AGED; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; EXANTHEMA; FEMALE; HUMANS; MALE; MEDICAL AUDIT; MIDDLE AGED; MINNESOTA; NEOPLASMS; PALLIATIVE CARE; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 79951712387     PISSN: 10966218     EISSN: None     Source Type: Journal    
DOI: 10.1089/jpm.2010.0258     Document Type: Article

References (12)

1. Tang PA, Tsao MS, Moore MJ: A review of erlotinib and its clinical use. Expert Opin Pharmacol 2006;7:177-193. (Pubitemid 43263257)
2. Wacker B, Nagrani T, Weinberg J, Witt K, Clark G, Cagnoni PJ: Correlation between development of rash and efficacy in patients treated with the epidermal growth factor receptor tyrosine kinase inhibitor erlotinib in two large phase III studies. Clin Cancer Res 2007;13:3913-3921. (Pubitemid 47037599)
3. Gandhi M, Oishi K, Zubal B, Lacouture ME: Unanticipated toxicities from anticancer therapies: Survivors' perspectives. Support Care Cancer 2010;18:1461-1468.
4. Wagner LI, Lacouture ME: Dermatologic toxicities associated with EGFR inhibitors: The clinical psychologist's perspective. Impact on health-related quality of life and implications for clinical management of psychological sequelae. Oncology 2007; 21(Suppl 5): 34-36.
5. Melosky B, Burkes R, Rayson D, Cekic V, Forde KA, Bank J, Feingold DL: Management of skin rash during EGFRtargeted monoclonal antibody treatment for gastrointestinal malignancies: Canadian recommendations. Curr Oncol 2009;16:16-26.
6. Scope A, Lieb JA, Dusza SW, Phelan DL, Myskowski PL, Saltz L, Halpern AC: A prospective randomized trial of topical pimecrolimus for cetuximab-associated acnelike eruption. J Am Acad Dermatol 2009;61:614-620.
7. Jatoi A, Rowland K, Sloan JA, Gross HM, Fishkin PA, Kahanic SP, Novotny PJ, Schaefer PL, Johnson DB, Tschetter LK, Loprinzi CL: Tetracycline to prevent epidermal growth factor receptor inhibitor-induced skin rashes: Results of a placebo-controlled trial from the North Central Cancer Treatment Group (N03CB). Cancer 2008;113:847-853.
8. Scope A, Agero AL, Dusza SW, Myskowski PL, Lieb JA, Saltz L, Kemeny NE, Halpern AC: Randomized doubleblind trial of prophylactic oral minocycline and topical tazarotene for cetuximab-associated acne-like eruption. J Clin Oncol 2007;25:5390-5396. (Pubitemid 350232214)
9. Mitchell EP, Lacouture ME, Shearer H, et al: Final STEPP results of prophylactic versus reactive skin toxicity treatment for panitumumab-related ST in patients with metastatic colorectal cancer [Abstract CRA4027]. J Clin Oncol 2009; 27(suppl):18s.
10. Jatoi A, Green EM, Rowland KM, Sargent DJ, Alberts SR: Clinical predictors of severe cetuximab-induced rash: Observations from 933 patients enrolled in North Central Cancer Treatment Group study N0147. Oncology 2009;77:120-123.
11. Solomon BM, Jatoi A: Rash from EGFR inhibitors: Opportunities and challenges for palliation. Curr Oncol Rep 2008; 10:304-308.
12. Jatoi A, Loprinzi CL: Adenosine triphosphate: Does it help cancer patients "get bigger and stronger"? J Clin Oncol 2002;20:362-363. (Pubitemid 34072516)